Safety of erlotinib treatment in outpatients with previously treated non-small-cell lung cancer in Japan期刊界 All Journals 搜尽天下杂志传播学术成果专业期刊搜索期刊信息化学术搜索

Safety of erlotinib treatment in outpatients with previously treated non-small-cell lung cancer in Japan

Authors:	Hiroki Nagai Shiro Tanaka Miyuki Niimi Nanae Seo Takahiko Sasaki Hiroshi Date Michiaki Mishima Hiroyasu Yasuda Kazuhiro Yanagihara

Affiliation:	(1) Outpatient Oncology Unit, Kyoto University Hospital, Kyoto 606-8507, Japan;(2) Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan;(3) Department of Clinical Trial Design and Management, Translational Research Center, Kyoto University Hospital, Kyoto 606-8507, Japan;(4) Department of Respiratory Medicine, Tohoku University School of Medicine, Sendai 980-8574, Japan;(5) Department of Thoracic Surgery, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan;(6) Department of Clinical Application, Tohoku University Translational Research Center, Sendai 980-8574, Japan;(7) Department of Translational Clinical Oncology, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan;

Abstract:	Purpose Erlotinib is the first epidermal growth factor receptor–tyrosine kinase inhibitor shown to provide a survival benefit for advanced non-small-cell lung cancer (NSCLC) patients. Adverse drug reactions of erlotinib in Japanese, which may be very different from those in Caucasians because of differences in genetic background, have not been fully reported. Therefore, we aimed to clarify the safety profile of erlotinib.

Keywords:
本文献已被 PubMed SpringerLink 等数据库收录！

设为首页 | 免责声明 | 关于勤云 | 加入收藏

Purpose